Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm’s disciplined, science-first approach to company building and investing. Earlier today, Halda Therapeutics announced its acquisition by Johnson & Johnson (NYSE: JNJ) for $3.05 billion, marking a historic moment for the Vida III portfolio. Hald